Press releases

2017

2017-11-13 22:50 Andreas Bhagwanis presentation at Swedish Shareholders Associations ”Stora Aktiedagen” in Stockholm

https://www.youtube.com/watch?v=pXhda3qlFWQ

2016

2016-08-31 10:45 Nanologica and Teva enter into a Feasibility Study Agreement

Nanologica has today announced that it enters into a Feasibility Study Agreement with Teva. Under the agreement, Nanologica will develop a customized drug...

2016-08-24 08:30 Nanologica enters into research collaboration with GSK

”We are excited about the collaboration with GSK. This is an early, but interesting project with the possibility to unlock new approaches to personalized...

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.

Press releases

Read more:

Categories

2017

2016